Fetal gene therapy’s progress calls into question the taboo on embryo editingnews2026-05-20T14:10:34+00:00May 20th, 2026|Endpoints News|
Parabilis reveals IPO plans the day after Regeneron deal as listings heat upnews2026-05-20T10:40:54+00:00May 20th, 2026|Endpoints News|
GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investornews2026-05-20T10:22:22+00:00May 20th, 2026|Endpoints News|
TrumpRx adds hundreds of generic medicines to sitenews2026-05-19T19:07:00+00:00May 19th, 2026|Endpoints News|
Another Paragon offshoot chooses reverse merger, this time for migraine drugsnews2026-05-19T18:56:01+00:00May 19th, 2026|Endpoints News|
Acceleron leaders and Westlake jumpstart new IPF biotechnews2026-05-19T18:15:10+00:00May 19th, 2026|Endpoints News|
Q&A: Novo research chief Petersen says streamlined R&D speeds discoverynews2026-05-19T15:22:01+00:00May 19th, 2026|Endpoints News|
Wave aims for monthly dosing with RNA editing treatment for AATDnews2026-05-19T15:19:59+00:00May 19th, 2026|Endpoints News|
Full-Life Technologies raises $150M; Quince’s reboot with pulmonary drugnews2026-05-19T14:38:23+00:00May 19th, 2026|Endpoints News|
